{"id":"NCT01959841","sponsor":"Maruho Co., Ltd.","briefTitle":"Phase III Study of ASP2151 in Herpes Zoster Patients","officialTitle":"Phase III Study of ASP2151 in Herpes Zoster Patients- A Double-blind, Valaciclovir-controlled Study","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-08","primaryCompletion":"2015-07","completion":"2015-07-10","firstPosted":"2013-10-10","resultsPosted":"2018-10-18","lastUpdate":"2018-11-27"},"enrollment":751,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Herpes Zoster"],"interventions":[{"type":"DRUG","name":"ASP2151","otherNames":[]},{"type":"DRUG","name":"valaciclovir","otherNames":[]}],"arms":[{"label":"ASP2151(200 mg)","type":"EXPERIMENTAL"},{"label":"ASP2151(400mg)","type":"EXPERIMENTAL"},{"label":"valaciclovir","type":"EXPERIMENTAL"}],"summary":"To evaluate the efficacy and safety of ASP2151 (200 mg and 400 mg) in comparison with valaciclovir (VACV) 3000 mg in patients with herpes zoster.","primaryOutcome":{"measure":"The Percentage of Participants Achieving Cessation of New Lesion Formation by Day 4 of Study Treatment","timeFrame":"4days","effectByArm":[{"arm":"ASP2151(200 mg)","deltaMin":69.6,"sd":null},{"arm":"ASP2151(400mg)","deltaMin":81.1,"sd":null},{"arm":"Valaciclovir","deltaMin":75.1,"sd":null}],"pValues":[{"comp":"OG001 vs OG002","p":"0.00000241"},{"comp":"OG000 vs OG002","p":"0.0688"}]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":3,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":252},"commonTop":["Nasopharyngitis","Alpha 1 microglobulin increased","Beta-N-acetyl-D-glucosaminidase increased","Fibrin degradation products increased","Headache"]}}